Valsartan, a common drug used to control hypertension and heart failure, is being recalled in 22 counties due to concerns its active pharmaceutical ingredient, N-Nitrosodimethylamine (NDMA), a known carcinogen, poses a cancer risk.

The U.S. Preventive Services Task Force (USPSTF) issued a Grade I recommendation for screening peripheral artery disease (PAD) and cardiovascular disease (CVD) risk with the ankle-brachial index (ABI), indicating current evidence is insufficient to recommend screening without signs or symptoms of disease.

Health insurance does little to protect low-income families from crippling financial hardship when a relative has atherosclerotic cardiovascular disease (ASCVD), according to a study published July 3 in JAMA Cardiology.

The FDA’s rules preventing sexually active gay men from donating blood are discriminatory and based on outdated fears, a physician wrote in an op-ed piece for the Los Angeles Times.

CMS is taking public comments ahead of a Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) meeting July 25 in which panelists will discuss procedural volume requirements for centers to begin and maintain a transcatheter aortic valve replacement (TAVR) program.

A company called Novoheart has created the first 3D heart organoid—a miniature version of the real thing—which contains a hollow chamber similar to one of the four in a normal human heart. According to a story published by Wired, these mini-hearts could be used to test the effects of drug treatments before expensive human trials are necessary.

Safety-net hospitals (SNHs) and smaller facilities were less likely to participate in the voluntary Bundled Payments for Care Improvement (BPCI) programs for cardiac services than larger centers with catheterization laboratories. These findings indicate that the outcomes observed from these programs may not be broadly applicable.

About a quarter of those who require insulin to treat diabetes use less than what is prescribed because of cost concerns, suggests a single-center study presented last week at the American Diabetes Association scientific sessions in Orlando.